Ionis Pharmaceuticals, Inc.
http://www.ionispharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ionis Pharmaceuticals, Inc.
Kalvista Stops Phase II HAE Prophylactic Trial Following Liver Enzyme Concerns
The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program.
US Supreme Court Preview: ‘Skinny’ Labels, FTC, And FCA – But No Tecfidera As Biogen Loses Bid
Teva’s carve-out fight with GSK over generic Coreg will see the Solicitor General weigh in. Amgen and Juno’s patent petitions remain pending, and the high court stays a Federal Circuit decision invalidating Novartis’ Gilenya patent.
Investors Get Selective As China Biotech Funding Rebounds
Oversee returnee-founded Chinese biotech start-ups Nuwacell and Arnatar secure $14m in series A and seed rounds respectively, while four other major deals backed by private equity and venture capital firms raise a combined $116m.
AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate
While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Akcea Therapeutics, Inc.
- Regulus Therapeutics, Inc.
- Symphony GenIsis, Inc.
- Isis Pharmaceuticals, Inc.